Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2022 | Evaluating new CAR constructs for chronic hepatitis B and HBV-associated HCC in the clinic

Ulrike Protzer • 8 Feb 2022
CAR-T Meeting 2022
General CAR-T

Ulrike Protzer, MD, Technical University of Munich, Munich, Germany, shares her excitement towards their chimeric antigen receptor (CAR) constructs being investigated as a novel clinical approach to treat chronic hepatitis B and hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

Disclosures

Share holder and board member of SCG Cell Therapy.
Ad hoc scientific advisor for AbbVie, Arbutus, Gilead, GSK, Johnson & Johnson, Roche, Sanofi, Sobi, and Vaccitech.

More from Ulrike Protzer

CAR-T therapy, a novel promising treatment option for chronic hepatitis B and HBV-associated HCC
1:33
CAR-T therapy, a novel promising treatment option for chronic hepatitis B and HBV-associated HCC
Ulrike Protzer • 8 Feb 2022
Rationale for using CAR-Ts to treat chronic hepatitis B
1:12
Rationale for using CAR-Ts to treat chronic hepatitis B
Ulrike Protzer • 8 Feb 2022
Using T-cell engager antibodies to treat chronic viral hepatitis B and HBV-associated HCC
2:00
Using T-cell engager antibodies to treat chronic viral hepatitis B and HBV-associated HCC
Ulrike Protzer • 8 Feb 2022

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals